Codman's 1924 address proposes the 'end-result idea': every hospital must follow every patient long enough to determine whether treatment succeeded, and if not, why not. Using the Registry of Bone Sarcoma as a working model, he argues for systematic multi-institutional outcomes collection as the foundation of scientific surgical practice. The paper is both a manifesto for outcomes accountability and a firsthand account of the institutional resistance that nearly killed the idea before it started.
Every tumor registry you will use as a resident — SEER, institutional bone tumor databases, multi-center sarcoma collaboratives. Exists because Codman argued in 1924 that a disease occurring at 2–3 per million cannot be understood by any single surgeon or hospital working alone.
The clinical implication is direct: when you see a rare tumor, your institutional experience is almost certainly insufficient to guide management. This is why bone sarcoma care is concentrated at high-volume centers, why tissue and imaging are submitted to multi-institutional registries, and why management decisions are made by tumor boards rather than individual surgeons.
Codman's registry form. Covering clinical history, imaging, pathology, treatment, and long-term follow-up. Is structurally identical to the data fields in every modern oncology registry. The format he invented is still in use.
The harder lesson from this paper: Codman found only five five-year survivors in three years of national data collection. That number reframes what 'success' looked like before limb-sparing surgery and modern chemotherapy. Understanding historical baselines is what makes you able to read and critique outcomes literature critically.
Codman's 1924 address proposes the 'end-result idea': every hospital must follow every patient long enough to determine whether treatment succeeded, and if not, why not. Using the Registry of Bone Sarcoma as a working model, he argues for systematic multi-institutional outcomes collection as the foundation of scientific surgical practice. The paper is both a manifesto for outcomes accountability and a firsthand account of the institutional resistance that nearly killed the idea before it started.
Every tumor registry you will use as a resident — SEER, institutional bone tumor databases, multi-center sarcoma collaboratives. Exists because Codman argued in 1924 that a disease occurring at 2–3 per million cannot be understood by any single surgeon or hospital working alone.
The clinical implication is direct: when you see a rare tumor, your institutional experience is almost certainly insufficient to guide management. This is why bone sarcoma care is concentrated at high-volume centers, why tissue and imaging are submitted to multi-institutional registries, and why management decisions are made by tumor boards rather than individual surgeons.
Codman's registry form. Covering clinical history, imaging, pathology, treatment, and long-term follow-up. Is structurally identical to the data fields in every modern oncology registry. The format he invented is still in use.
The harder lesson from this paper: Codman found only five five-year survivors in three years of national data collection. That number reframes what 'success' looked like before limb-sparing surgery and modern chemotherapy. Understanding historical baselines is what makes you able to read and critique outcomes literature critically.